Factors affecting high-sensitivity cardiac troponin T elevation in Japanese metabolic syndrome patients

Takashi Hitumoto1
Kohji Shirai2

1Hitumoto Medical Clinic, Yamaguchi, Japan; 2Department of Vascular Function (donated), Sakura Hospital, Toho University School of Medicine, Chiba, Japan

Purpose: The blood concentration of cardiac troponin T (ie, high-sensitivity cardiac troponin T [hs-cTnT]), measured using a highly sensitive assay, represents a useful biomarker for evaluating the pathogenesis of heart failure or predicting cardiovascular events. However, little is known about the clinical significance of hs-cTnT in metabolic syndrome. The aim of this study was to examine the factors affecting hs-cTnT elevation in Japanese metabolic syndrome patients.

Patients and methods: We enrolled 258 metabolic syndrome patients who were middle-aged males without a history of cardiovascular events. We examined relationships between hs-cTnT and various clinical parameters, including diagnostic parameters of metabolic syndrome.

Results: There were no significant correlations between hs-cTnT and diagnostic parameters of metabolic syndrome. However, hs-cTnT was significantly correlated with age (\(P<0.01\)), blood concentrations of brain natriuretic peptide (\(P<0.01\)), reactive oxygen metabolites (markers of oxidative stress, \(P<0.001\)), and the cardio–ankle vascular index (marker of arterial function, \(P<0.01\)). Furthermore, multiple regression analysis revealed that these factors were independent variables for hs-cTnT as a subordinate factor.

Conclusion: The findings of this study indicate that in vivo oxidative stress and abnormality of arterial function are closely associated with an increase in hs-cTnT concentrations in Japanese metabolic syndrome patients.

Keywords: troponin, metabolic syndrome, risk factor, oxidative stress, cardio–ankle vascular index

Introduction

The pathogenesis of metabolic syndrome is considered as a multiple risk factor clustering, which is caused by visceral fat accumulation, in Japan.1 The Japanese Committee for the Diagnostic Criteria of Metabolic Syndrome adopted a visceral fat area of 100 cm² as the cutoff point, which was estimated by computed tomography in both men and women. Furthermore, the waist circumference corresponding to a visceral fat area of 100 cm² was confirmed as 85 cm in men and 90 cm in women. According to this concept, in 2005, the Japanese Committee for the Diagnostic Criteria of Metabolic Syndrome defined metabolic syndrome as the presence of two or more clinical abnormalities (three abnormalities: dyslipidemia [serum triglyceride concentrations \(\geq 150\) mg/dL and/or serum high-density lipoprotein cholesterol concentrations < 40 mg/dL or under treatment], elevated blood pressure levels [systolic blood pressure \(\geq 130\) mmHg and/or diastolic pressure \(\geq 85\) mmHg or under treatment], and elevated blood glucose levels [fasting blood glucose \(\geq 110\) mg/dL or under treatment]), in addition to visceral fat obesity (waist circumference: 85 cm or more in men and 90 cm or more in women).2

Metabolic syndrome is considered as not only an important cardiovascular risk factor...
but also a contributor to the development of type 2 diabetes in Japan, even though the definition of metabolic syndrome in Japan is different from that in other countries.

Clinically, the blood concentration of cardiac troponin T, a component of the troponin complex, is used as a diagnostic tool for acute myocardial infarction, because cardiac troponin T is rapidly released from the myocardium to the blood following myocardial damage. Furthermore, recent clinical and epidemiological studies have demonstrated that the blood concentration of cardiac troponin T (hs-cTnT), measured using a highly sensitive assay, represents a useful biomarker for evaluating the pathogenesis of heart failure or predicting cardiovascular events. Several reports exist concerning relationships between hs-cTnT and clinical parameters such as age-related markers, in Japan or other countries. However, little is known about the clinical significance of hs-cTnT in metabolic syndrome. In the present study, we attempted to clarify the factors important for hs-cTnT elevation in metabolic syndrome from the perspective of primary cardiovascular events.

**Patients and methods**

**Study population**

This study was conducted at the Hitsumoto Medical Clinic in Shimonoseki City, Japan, between September 2011 and August 2013. The study population comprised 258 metabolic syndrome patients who were middle-aged males diagnosed using the Japanese metabolic syndrome criteria. Subjects with a history of cardiovascular disease or those using medications such as antihyperlipidemic, antihypertensive, or antidiabetic drugs were excluded. All participants provided informed consent, and the study protocol was approved by the Local Ethics Committee of the Hitsumoto Medical Clinic.

**Estimation of cardiovascular risk factors**

Diagnostic parameters of metabolic syndrome in the Japanese criteria and various clinical parameters, including hs-cTnT concentrations, were examined. In this study, the cardio–ankle vascular index (CAVI) was evaluated as a marker of arterial function. CAVI was measured by a standard method described previously. Briefly, the brachial and ankle pulse waves were determined using inflatable cuffs with the pressure maintained between 30 and 50 mmHg to ensure that the cuff pressure had a minimal effect on the systemic hemodynamics. Blood pressure and pulse pressure were determined simultaneously. These measurements were obtained with the subject in the supine position. CAVI was measured after the subject had rested for 10 minutes in a quiet room.

**Blood sampling**

Blood samples were collected from the antecubital vein in the morning after 12 hours of fasting. Total cholesterol and triglyceride concentrations were measured using standard enzymatic methods. Serum high-density lipoprotein cholesterol concentrations were measured by selective inhibition. Serum low-density lipoprotein cholesterol concentrations were calculated using the Friedewald formula; subjects with serum triglyceride concentrations ≥400 mg/dL were excluded because of the low sensitivity of this method. Glucose and insulin concentrations were measured using the glucose oxidase method and an enzyme immunoassay, respectively. To measure insulin resistance, we calculated homeostatic model assessment of insulin resistance (HOMA-IR) as follows: HOMA-IR = fasting glucose concentration (mg/dL) × fasting insulin concentration (µg/mL)/405. Estimated glomerular filtration rate (eGFR) was calculated using the adjusted Modification of Diet in Renal Disease Study equation, which was proposed by the working group of the Japanese Chronic Kidney Disease Initiative. The blood concentration of brain natriuretic peptide was measured using a commercial kit (SHIONOSPOT Reader; Shionogi and Co, Ltd, Osaka, Japan). High-sensitivity C-reactive protein (hs-CRP) concentration was measured using high-sensitivity, latex-enhanced immunonephelometry. The derivated reactive oxygen metabolites test, which reflects blood hydroperoxide concentrations, was performed using a commercial device (Diacron, Grosseto, Italy). hs-cTnT concentration was measured using a commercial kit (Roche Diagnostics, Rotkreuz, Switzerland). In this assay, the lower limit of detection was 0.003 ng/mL.

**Statistical analysis**

A commercially available statistical software program (Stat View-J 5.0; HULINKS Inc., Tokyo, Japan) was used for all statistical analyses. Data are expressed as mean ± standard deviation. Between-group comparisons were performed using the Student’s *t*-test or Mann–Whitney’s *U*-test, and the correlation coefficient was estimated using Spearman’s rank correlation analysis. To clarify the independent factors for hs-cTnT elevation, we performed multiple regression analysis for hs-cTnT as a subordinate factor. A *P*-value of <0.05 was considered statistically significant.

**Results**

Patient characteristics are shown in Table 1. hs-cTnT was detected in 226 patients (88%). Age, hs-CRP concentrations,
Table 1 Patient characteristics

| Parameter                        | All              | hs-cTnT detection | hs-cTnT nondetection |
|----------------------------------|------------------|-------------------|----------------------|
| N                                | 258              | 32                | 226                  |
| Age (years)                      | 63±11            | 56±7              | 64±11*               |
| Smoking (%)                      | 77 (30)          | 7 (22)            | 70 (31)              |
| Body mass index (Kg/m²)          | 24.7±3.0         | 24.0±3.0          | 24.8±3.0             |
| Diagnostic parameters of Mets    |                  |                   |                      |
| Waist circumference (cm)         | 89±5             | 89±4              | 89±5                 |
| Triglyceride (mg/dL)             | 203±60           | 193±55            | 204±61               |
| HDL cholesterol (mg/dL)          | 44±14            | 43±10             | 44±15                |
| Systolic BP (mmHg)               | 141±20           | 141±18            | 141±21               |
| Diastolic BP (mmHg)              | 89±14            | 87±13             | 89±14                |
| Fasting blood glucose (mg/dL)    | 111±15           | 110±16            | 111±15               |
| Immunoreactive insulin (µg/mL)   | 9.6±4.2          | 9.8±3.4           | 9.6±4.3              |
| Log-HOMA-IR                      | 0.4±0.3          | 0.4±0.2           | 0.4±0.3              |
| Total cholesterol (mg/dL)        | 226±43           | 230±44            | 225±42               |
| LDL cholesterol (mg/dL)          | 141±40           | 149±40            | 140±40               |
| Log-hs-CRP (mg/L)                | –1.1±0.4         | –1.3±0.6          | –1.0±0.4***          |
| d-ROMs test (U Carr)             | 321±77           | 266±46            | 329±77*              |
| Log-BNP (pg/mL)                  | 1.5±0.5          | 1.2±0.3           | 1.5±0.5***           |
| eGFR (mL/min/1.73 m²)            | 60±21            | 75±17             | 58±21*               |
| Cardio-ankle vascular index      | 9.1±1.5          | 8.1±1.1           | 9.2±2.1*             |
| Log-hs-cTnT (ng/mL)              | –2.1±0.2         | –2.1±0.2          | –2.1±0.2             |

Note: Data are expressed mean ± SD. *P<0.001; **P<0.05; ***P<0.01.
Abbreviations: Mets, metabolic syndrome; hs-cTnT, high-sensitivity cardiac troponin T; BnP, brain natriuretic peptide; HOMA-IR, homeostatic model assessment of insulin resistance; LDL, low-density lipoprotein; HDL, high-density lipoprotein; hs-CRP, high sensitivity C-reactive protein; d-ROMs, derivatives of reactive oxygen metabolites; BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate.

Table 2 Correlation between hs-cTnT and various clinical parameters in hs-cTnT detectable patients

| Parameter                  | r    | P value |
|----------------------------|------|---------|
| Age                        | 0.35 | <0.01   |
| Smoking (No =0, Yes =1)    | 0.06 | 0.39    |
| Body mass index            | 0.11 | 0.10    |
| Waist circumference        | 0.09 | 0.20    |
| Triglyceride               | –0.21| 0.06    |
| HDL cholesterol            | 0.11 | 0.32    |
| Systolic BP                | –0.07| 0.57    |
| Diastolic BP               | 0.02 | 0.86    |
| Fasting blood glucose      | –0.02| 0.89    |
| Immunoreactive insulin     | –0.10| 0.37    |
| Log-HOMA-IR                | –0.11| 0.30    |
| Total cholesterol          | –0.11| 0.34    |
| LDL cholesterol            | –0.07| 0.56    |
| Log-hs-CRP                 | 0.18 | <0.01   |
| d-ROMs test                | 0.43 | <0.001  |
| Log-BNP                    | 0.32 | <0.01   |
| eGFR                       | –0.24| <0.05   |
| Cardio-ankle vascular index| 0.36 | <0.01   |

Note: (n=226).
Abbreviations: hs-cTnT, high-sensitivity cardiac troponin T; BP, blood pressure; HOMA-IR, homeostatic model assessment of insulin resistance; LDL, low-density lipoprotein; HDL, high-density lipoprotein; hs-CRP, high sensitivity C-reactive protein; d-ROMs, derivatives of reactive oxygen metabolites; BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate.

Table 3 Multiple regression analysis for hs-cTnT

| Explanatory factor | Standard correlation coefficient | t value | P value |
|--------------------|---------------------------------|---------|---------|
| d-ROMs test        | 0.37                            | 5.7     | <0.001  |
| Log-BNP            | 0.16                            | 2.6     | <0.01   |
| CAVI                | 0.13                            | 2.2     | <0.05   |
| Age                | 0.11                            | 2.0     | <0.05   |
| eGFR               | –0.10                           | –1.4    | 0.16    |
| Log-hs-CRP         | 0.06                            | 0.8     | 0.40    |

Note: R²=0.28, F value =16.2, P<0.001.
Abbreviations: hs-cTnT, high-sensitivity cardiac troponin T; hs-CRP, high sensitivity C-reactive protein; d-ROMs, derivatives of reactive oxygen metabolites; BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; CAVI, cardio-ankle vascular index.

Discussion

Recently, Pervanidou et al18 examined the relationship of circulating concentrations of hs-cTnT with metabolic syndrome in childhood. They reported that hs-cTnT in obese children with metabolic syndrome was higher than that in obese children without metabolic syndrome and nonobese children; moreover, hs-cTnT did not differ between obese children without metabolic syndrome and nonobese children. These results suggest that the presence of metabolic syndrome resulted in hs-cTnT elevation at an early stage. Among diagnostic parameters of metabolic syndrome, high blood glucose concentrations and high blood pressure were reported to cause myocardial damage via dysfunction of microcirculation, oxidative stress, or other pathways.19–21 In clinical studies, however, relationships among blood glucose concentrations, blood pressure levels, and blood concentrations of cardiac ROM serum concentrations, blood concentrations of brain natriuretic peptide, and CAVI were significantly higher, and eGFR was significantly lower in patients with detectable hs-cTnT. However, diagnostic parameters of metabolic syndrome were not significantly different between the two groups. Correlations between hs-cTnT and various clinical parameters in hs-cTnT-positive patients are shown in Table 2.

The results of multiple regression analysis are shown in Table 3. Blood concentrations of brain natriuretic peptide, ROM serum concentrations, CAVI, and age were selected as independent variables for hs-cTnT as a subordinate factor.

Abreviations: Mets, metabolic syndrome; hs-cTnT, high-sensitivity cardiac troponin T; BP, blood pressure; HOMA-IR, homeostatic model assessment of insulin resistance; LDL, low-density lipoprotein; HDL, high-density lipoprotein; hs-CRP, high sensitivity C-reactive protein; d-ROMs, derivatives of reactive oxygen metabolites; BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate.
troponin were controversial.22–25 Wallace et al22 reported that diabetes mellitus was independently associated with cTnT elevation in the general population. However, Everett et al23 reported that no significant relationship was observed between hemoglobin A1c levels and hs-cTnT in nondiabetic subjects. McKie et al24 reported that hypertension was significantly associated with hs-cTnT in the general population. However, Hoshide et al25 reported that blood pressure-lowering therapy using losartan plus hydrochlorothiazide did not lead to a significant decrease in hs-cTnT, even though blood pressure levels were decreased. Insulin resistance has been considered to have an important role in the pathogenesis of metabolic syndrome. Furthermore, some clinical studies reported a correlation between insulin resistance and myocardial damage.26,27 In the present study, however, HOMA-IR showed no significant correlation with hs-cTnT. It is well known that abnormal adipocytokine secretion is associated with the pathogenesis of metabolic syndrome. Furthermore, some basic or clinical studies reported relationships between adipocytokines such as adiponectin or resistin and myocardial damage.28,29 Abnormal adipocytokine secretion may be an important factor for hs-cTnT elevation in metabolic syndrome. In this study, adipocytokine concentrations were not assessed; therefore, further studies are warranted to evaluate the relationship of adipocytokines with hs-cTnT.

Oxidative stress is known to be an important component in the progression of heart failure, and several pathways by which oxidative stress leads to myocardial damage have been identified, including dysfunction of the mitochondrial electron transport complex, activity of nicotinamide adenine dinucleotide phosphate oxidase, and apoptosis of myocardial cells.30–32 Furthermore, this study revealed the importance of oxidative stress for myocardial damage in metabolic syndrome and subclinical heart failure. Among a number of markers of oxidative stress, the derivated reactive oxygen metabolites test is considered clinically useful to evaluate oxidative stress in vivo, because the measurement of ROM serum concentrations is accurate and simple and it can be performed rapidly.16,33 Furthermore, recent clinical studies have reported a relationship between ROM and cardiovascular disease.34,35 Therefore, the measurement of ROM serum concentrations is expected to predict the degree of subclinical myocardial damage or primary cardiovascular events in metabolic syndrome. The stiffness index \( \beta \) is known to reflect the stiffness of the aortic artery, and CAVI is reported to reflect the stiffness index \( \beta \) of the thoracic aorta or the common carotid artery.36 CAVI is considered as a useful physiological marker for evaluating arterial stiffness, except in patients with chronic arterial fibrillations or peripheral arterial disease, because of the low reliability of CAVI. In recent years, several studies have indicated the importance of left ventricular dysfunction in the occurrence of heart failure or the progression of myocardial damage;37 furthermore, increases in aortic artery stiffness are known to cause left ventricular dysfunction. Sakane et al38 reported a significant relationship between CAVI and left ventricular dysfunction using ultrasonic echocardiography. Therefore, the relationship between hs-cTnT and CAVI identified in this study was considered to reflect myocardial damage via left ventricular dysfunction by an increase in vascular resistance or afterload. Another clinical study reported that CAVI reflected endothelial dysfunction.39 Endothelial dysfunction has also been known to cause left ventricular dysfunction or myocardial damage;40,41 therefore, the significant correlation of hs-cTnT with CAVI in metabolic syndrome patients may be partly explained by endothelial dysfunction.

This study had several limitations. First, ultrasonic echocardiography, coronary angiography, or multidetector computed tomography angiography was not performed; therefore, cardiovascular diseases such as heart failure or coronary artery disease may have remained undetected in patients. Second, female subjects were not included. The proportion of metabolic syndrome patients in the general Japanese female population is very small (incidence: 12.1% in males, 1.7% in females).42 Therefore, analysis of metabolic syndrome in females diagnosed by the Japanese criteria is very difficult in the single-unit range. The relationship between hs-cTnT and metabolic syndrome in the Japanese female population will be discussed in large-scale studies. Third, this study was cross-sectional, and its sample size was relatively small. A large number of prospective studies, including interventional therapies, are required to clarify the clinical significance of hs-cTnT, CAVI, and ROMs with metabolic syndrome.

**Conclusion**

The study findings indicate that in vivo oxidative stress and abnormalities of arterial function are closely associated with increases in hs-cTnT concentration in Japanese metabolic syndrome patients.

**Disclosure**

The authors have no conflicts of interest to declare.

**References**

1. Nakamura T, Tokunaga K, Shimomura I, et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. *Atherosclerosis*. 1994;107(2):239–246.
2. Matsuzawa Y. Metabolic syndrome-definition and diagnostic criteria in Japan. J Atheroscler Thromb. 2005;12(6):301.

3. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–1132.

4. Takeuchi H, Saitoh S, Takagi S, et al. Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese men—the Tanno and Sobetsu study. Hypertens Res. 2005;28(3):203–208.

5. Hitsumoto T, Takahashi M, Iizuka T, Shirai K. Relationship between metabolic syndrome and early stage coronary atherosclerosis. J Atheroscler Thromb. 2007;14(6):294–302.

6. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361(9):858–867.

7. Latini R, Masson S, Andan IS, et al. Val-HeFT Investigators. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation. 2007;116(11):1242–1249.

8. Sato Y, Yamamoto E, Sawa T, et al. High-sensitivity cardiac troponin T in essential hypertension. J Cardiol. 2011;58(3):226–231.

9. Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011;123(13):1367–1376.

10. Setsuta K, Kitahara Y, Arai M, Obhayashi T, Seino Y, Mizuno K. Elevated cardiac troponin T predicts adverse outcomes in hypertensive patients. Int Heart J. 2011;52(3):164–169.

11. Chenevier-Gobeaux C, Bailleul S, Mzabi A, Blanc MC, Lefevre G. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419.

12. Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CA VI). J Int Med. 2013;59(3–4):333–336.

13. Vassalle C, Bianchi S, Battaglia D, Landi P, Bianchi F, Carpeggiani C. Adiponectin protects rat myocardium against chronic intermittent hypoxia-induced injury via inhibition of endoplasmic reticulum stress. PLoS One. 2014;9(4):e94545.

14. Kwon SH, Pimentel DR, Remondino A, Sawyer DB, Colucci WS. H(2)O(2) regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways. J Mol Cell Cardiol. 2003;35(6):615–621.

15. Fukui T, Yamauchi K, Maruyama M, Yasuda T, Kohno M, Abe Y. Significance of measuring oxidative stress in lifestyle-related diseases from the viewpoint of correlation between d-ROMs and BAP in Japanese subjects. Hyperpertens Res. 2011;34(9):1041–1045.

16. Kotani K, Koibuchi H, Miyamoto M, Yamada T, Taniguchi N, et al. The relationship of carotid intima-media thickness in subjects with hypercholesterolemia with serum cystatin C levels in patients with coronary artery disease. J Atheroscler Thromb. 2012;19(8):712–717.

17. Takaki A, Ogawa H, Wakeyama T, et al. Cardio-ankle vascular index is a new noninvasive parameter of arterial stiffness. Circ J. 2007;71(11):1710–1714.

18. Takagi H, Kobayashi K, Kogajiya S, et al. Association of carotid arterial stiffness to left ventricular diastolic dysfunction in untreated hypertension. Cardiovasc Dis. 2012;70(3):223–231.

19. Sakane K, Miyoshi T, Doi M, et al. Association between high-sensitivity cardiac troponin concentrations in the community. Clin Chem. 2013;59(7):1099–1107.

20. Miyoshi T, Shishido T, Kiribayashi N, et al. Impact of insulin resistance on silent and ongoing myocardial damage in normal subjects: the Takahata study. Exp Diabetes Res. 2012;2012:810598.

21. Ueta K, Amano T, Harada K, et al. Impact of insulin resistance on post-procedural myocardial injury and clinical outcomes in patients who underwent elective coronary interventions with drug-eluting stents. JACC Cardiovasc Interv. 2012;5(11):1159–1167.

22. Ling W, Zhang X, Huang H, et al. Adiponectin protects rat myocardium against chronic intermittent hypoxia-induced injury via inhibition of endoplasmic reticulum stress. PLoS One. 2014;9(4):e94545.

23. Li SY, Yang X, Ceylan-Isik AF, Du M, Sreejayani N, Ren J. Cardiac contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco(endo)plasmic reticulum Ca2+-ATPase and myosin heavy chain isozyme switch. Diabetologia. 2006;49(6):1434–1446.

24. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010;11(1):31–39.

25. Kwon SH, Pimentel DR, Remondino A, Sawyer DB, Colucci WS. H(2)O(2) regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways. J Mol Cell Cardiol. 2003;35(6):615–621.

26. Fukui T, Yamauchi K, Maruyama M, Yasuda T, Kohno M, Abe Y. Significance of measuring oxidative stress in lifestyle-related diseases from the viewpoint of correlation between d-ROMs and BAP in Japanese subjects. Hypertens Res. 2011;34(9):1041–1045.

27. Kotani K, Koibuchi H, Miyamoto M, Yamada T, Taniguchi N. Relationship between reactive oxygen metabolites and carotid intima-media thickness in subjects with hypercholesterolemia. Med Prin Pract. 2010;19(6):496–498.

28. Vassalle C, Bianchi S, Battaglia D, Landi P, Bianchi F, Carpeggiani C. Elevated levels of oxidative stress as a prognostic predictor of major adverse cardiovascular events in patients with coronary artery disease. J Atheroscler Thromb. 2012;19(8):712–717.

29. Takagi H, Ogawa H, Wakeyama T, et al. Cardio-ankle vascular index is a new noninvasive parameter of arterial stiffness. Circ J. 2007;71(11):1710–1714.

30. Takagi H, Kobayashi K, Kogajiya S, et al. The relationship of carotid arterial stiffness to left ventricular diastolic dysfunction in untreated hypertension. Cardiovasc Dis. 2012;70(3):223–231.

31. Sakane K, Miyoshi T, Doi M, et al. Association of new arterial stiffness parameter, the cardio-ankle vascular index, with left ventricular diastolic dysfunction in untreated hypertension. Hypertens Res. 2012;35(3):261–267.
41. Martí V, Aymat R, Ballester M, García J, Carrió I, Augé JM. Coronary endothelial dysfunction and myocardial cell damage in chronic stable idiopathic dilated cardiomyopathy. *Int J Cardiol.* 2002;82(3):237–245.

42. Arai H1, Yamamoto A, Matsuzawa Y, et al. Prevalence of metabolic syndrome in the general Japanese population in 2000. *J Atheroscler Thromb.* 2006;13(4):202–208.